Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:INDVNASDAQ:VBLTNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$70.82+0.8%$66.45$52.50▼$73.72$1.54B0.56287,631 shs287,058 shsINDVIndivior$11.50-1.8%$9.92$7.33▼$18.59$1.58B0.98991,063 shs1.06 million shsVBLTVascular Biogenics$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shsVERAVera Therapeutics$22.62+2.8%$24.48$18.53▼$51.61$1.44B1.28771,292 shs1.49 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-3.16%-0.69%+4.07%+17.49%+4.32%INDVIndivior-1.68%-0.43%+27.87%+6.17%-35.54%VBLTVascular Biogenics0.00%0.00%0.00%0.00%0.00%VERAVera Therapeutics-13.79%-8.29%+3.28%-42.25%-51.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals4.4935 of 5 stars3.53.00.03.33.33.31.3INDVIndivior3.1809 of 5 stars3.63.00.00.02.21.71.9VBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/AVERAVera Therapeutics3.4149 of 5 stars4.63.00.00.03.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1313.14% UpsideINDVIndivior 3.25Buy$15.0030.49% UpsideVBLTVascular Biogenics 0.00N/AN/AN/AVERAVera Therapeutics 3.18Buy$63.80182.05% UpsideCurrent Analyst Ratings BreakdownLatest VBLT, INDV, VERA, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.003/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/14/2025ANIPANI PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.003/12/2025ANIPANI PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.003/5/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$84.00 ➝ $86.003/4/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$77.00 ➝ $71.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.51$7.84 per share9.03$21.13 per share3.35INDVIndivior$1.17B1.35$2.33 per share4.94N/A∞VBLTVascular Biogenics$660K0.00N/AN/A$0.32 per share0.00VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.14N/A16.82N/A-1.28%15.87%6.88%5/9/2025 (Estimated)INDVIndivior$2M-$0.31N/A6.72N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)VBLTVascular Biogenics-$32.30M-$0.21N/AN/AN/AN/A-73.45%-54.11%N/AVERAVera Therapeutics-$95.99M-$2.75N/AN/AN/AN/A-50.13%-39.50%5/8/2025 (Estimated)Latest VBLT, INDV, VERA, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37N/AN/AN/A$179.75 millionN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million2/26/2025Q4 2024VERAVera Therapeutics-$0.83-$0.72+$0.11-$0.72N/AN/A2/20/2025Q4 2024INDVIndivior$0.32$0.32N/A$0.07$262.35 million$298.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97INDVIndiviorN/A0.830.65VBLTVascular BiogenicsN/A4.634.63VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%INDVIndivior60.33%VBLTVascular Biogenics0.96%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%INDVIndiviorN/AVBLTVascular Biogenics6.13%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.77 million18.36 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableVERAVera Therapeutics4063.75 million49.58 millionOptionableVBLT, INDV, VERA, and ANIP HeadlinesRecent News About These CompaniesHC Wainwright Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)May 7 at 11:27 AM | marketbeat.comVera Therapeutics shares fall as Q1 loss exceeds estimatesMay 6 at 7:19 PM | investing.comVera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 6 at 8:00 AM | globenewswire.comHC Wainwright Begins Coverage on Vera Therapeutics (NASDAQ:VERA)May 6 at 2:47 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Holdings Lessened by Schonfeld Strategic Advisors LLCMay 5 at 5:10 AM | marketbeat.comVera Therapeutics (VERA) Expected to Announce Earnings on ThursdayMay 3, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Buy" from AnalystsMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)May 2, 2025 | marketbeat.comVera Therapeutics (VERA) to Release Quarterly Earnings on ThursdayMay 1, 2025 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Buy" from BrokeragesMay 1, 2025 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by First Light Asset Management LLCApril 30, 2025 | marketbeat.comRaymond James Financial Inc. Purchases Shares of 69,724 Vera Therapeutics, Inc. (NASDAQ:VERA)April 30, 2025 | marketbeat.comVoya Investment Management LLC Buys 591,682 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)April 29, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Reduces Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 29, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Price T Rowe Associates Inc. MDApril 29, 2025 | marketbeat.comBarclays PLC Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 29, 2025 | marketbeat.comRenaissance Technologies LLC Makes New Investment in Vera Therapeutics, Inc. (NASDAQ:VERA)April 29, 2025 | marketbeat.comNovartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New Therapeutic Paradigm | DelveInsightApril 28, 2025 | prnewswire.co.ukDecheng Capital LLC Reduces Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 28, 2025 | marketbeat.comLord Abbett & CO. LLC Increases Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 28, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Buys 431,178 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)April 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketCan IBM’s Q1 Earnings Spark a Breakout for the Stock?By Jeffrey Neal Johnson | April 23, 2025View Can IBM’s Q1 Earnings Spark a Breakout for the Stock?Is McDonald’s Stock Serving a Value Meal to Investors? By Jeffrey Neal Johnson | April 13, 2025View Is McDonald’s Stock Serving a Value Meal to Investors? 3 Dividend Kings Outshining the Market in 2025By Ryan Hasson | April 30, 2025View 3 Dividend Kings Outshining the Market in 2025VBLT, INDV, VERA, and ANIP Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$70.82 +0.55 (+0.78%) Closing price 04:00 PM EasternExtended Trading$70.42 -0.40 (-0.57%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Indivior NASDAQ:INDV$11.50 -0.21 (-1.75%) Closing price 03:59 PM EasternExtended Trading$11.45 -0.04 (-0.39%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Vascular Biogenics NASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.Vera Therapeutics NASDAQ:VERA$22.62 +0.61 (+2.77%) Closing price 04:00 PM EasternExtended Trading$22.98 +0.36 (+1.61%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
